OTCMKTS:PXXLF Poxel (PXXLF) Stock Price, News & Analysis → The most important AI company you've never heard of (From Manward Press) (Ad) Free PXXLF Stock Alerts $0.70 0.00 (0.00%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.7050-Day Range$0.55▼$0.7052-Week Range$0.55▼$0.70VolumeN/AAverage VolumeN/AMarket Capitalization$20.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Poxel alerts: Email Address Ad Manward PressThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company About Poxel Stock (OTCMKTS:PXXLF)Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.Read More PXXLF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PXXLF Stock News HeadlinesMay 14 at 6:12 PM | msn.comGoogle I/O 2024 live: get ready for Android 15, Pixel products and AI advancesMay 14 at 4:43 AM | msn.comBest Hand-Drawn Video GamesMay 10, 2024 | msn.comThe Best Puzzle Games On SteamMay 10, 2024 | msn.com7 Things We Wish We Knew Before Playing Animal WellMay 9, 2024 | msn.comAnimal Well ReviewMay 9, 2024 | msn.comREVIEW: ‘Animal Well’ Delivers Excellence That Won’t Be For Everyone (PC)May 9, 2024 | msn.comAnimal Well review: must-play Metroidvania is full of rewarding secretsMay 9, 2024 | msn.comAnimal Well - ReviewMay 7, 2024 | msn.comGoogle's Pixel Tablet Is $100 Less Without the DockMay 2, 2024 | msn.comHellblade 2, Paper Mario, and 17 Other Games To Get Excited For In MayMay 2, 2024 | msn.comWordle Answer Today (May 2024) - Solution History!May 1, 2024 | msn.com10 addictive Android games to play on your phone or tabletMay 1, 2024 | msn.comWhat’s new in May 2024: 7 games that you need to play this monthApril 30, 2024 | msn.comThis highly rated game has arrived on Xbox Game PassApril 29, 2024 | businesswire.comPoxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results ReleaseApril 29, 2024 | msn.comGoogle Pixel 8A ad leak confirms most rumors weeks before launchApril 28, 2024 | msn.com10 Best Video Games Coming Out In May 2024April 27, 2024 | mirror.co.uk7 best indie games released in April 2024 – don't sleep on these overlooked gemsApril 26, 2024 | yahoo.comWalton County kids practice motor skills at Special Olympics YAP eventApril 26, 2024 | yahoo.comCould Bob Graham succeed in current political climate?April 26, 2024 | msn.comEpic Games Store: New Free Game of the Week Revealed (April 25)April 25, 2024 | msn.comNintendo 3DS: Why It Rules As The Ultimate HandheldApril 20, 2024 | msn.comAndroid phones are getting a powerful parental control upgradeApril 19, 2024 | msn.com9 Fantastic Co-Op Cozy Games for CouplesApril 18, 2024 | msn.comHere's Everything From April 2024's Indie World ShowcaseSee More Headlines Receive PXXLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poxel and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:PXXLF CUSIPN/A CIKN/A Webwww.poxel.com Phone33-4-37-37-20-10Fax043-770-8815Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$710,000.00 Price / Sales28.54 Cash FlowN/A Price / Cash FlowN/A Book Value($0.66) per share Price / Book-1.06Miscellaneous Outstanding Shares28,950,000Free FloatN/AMarket Cap$20.27 million OptionableNot Optionable Beta0.44 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Thomas Kuhn M.B.A.Pharm D MBA, Pharm.D., Co-Founder, CEO & DirectorDr. Sébastien Bolze Ph.D.Pharm D Ph.D., Pharm.D., Co-Founder, COO and Executive VP of Project Management, Non Clinical & Manufacturing OperationsDr. Pascale Fouqueray-Grellier M.D.Ph.D., Co-Founder and Executive VP of Clinical Development & Regulatory AffairsDr. Sophie Hallakou-Bozec Ph.D.Co-Founder and Executive VP of R&D Pharmacology & Scientific CommunicationArthur RouilleInvestor Relations OfficerMr. Quentin DurandExecutive VP, Chief Legal Officer & Head of Corporate Social ResponsibilityMs. Sylvie BertrandVice President of Human ResourcesMore ExecutivesKey CompetitorsNicoxOTCMKTS:NICXFElse NutritionOTCMKTS:BABYFPreveCeutical MedicalOTCMKTS:PRVCFSynlogicNASDAQ:SYBXLexaria BioscienceOTCMKTS:LXRPView All Competitors PXXLF Stock Analysis - Frequently Asked Questions How have PXXLF shares performed in 2024? Poxel's stock was trading at $0.60 on January 1st, 2024. Since then, PXXLF stock has increased by 16.7% and is now trading at $0.70. View the best growth stocks for 2024 here. How do I buy shares of Poxel? Shares of PXXLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PXXLF) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon to Transform U.S. Economy? Porter & CompanyThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poxel S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.